Compugen Stock

Compugen Equity

The The Equity of Compugen (CGEN) as of Sep 4, 2026 is 102.73 M USD. In the previous year, The Equity was 54.91 M USD — a change of 87.08% (higher).

Equity

102.73 MUSD

YoY

87.08%

Last updated:

In 2026, Compugen's equity was 102.73 M USD, a 87.08% increase from the 54.91 M USD equity in the previous year.

The Compugen Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
37.24 M USD
Jan 1, 2019
38.32 M USD
Jan 1, 2020
119.78 M USD
Jan 1, 2021
106.69 M USD
Jan 1, 2022
77.68 M USD
Jan 1, 2023
65.56 M USD
Jan 1, 2024
54.91 M USD
Jan 1, 2025
102.73 M USD
The Compugen Equity history
YEAREquityYoY
102.73 MUSD+87.08%
54.91 MUSD-16.24%
65.56 MUSD-15.60%
77.68 MUSD-27.19%
106.69 MUSD-10.93%
119.78 MUSD+212.58%
38.32 MUSD+2.89%
37.24 MUSD+27.12%
29.30 MUSD-53.88%
63.52 MUSD-29.34%
89.90 MUSD-15.17%
105.98 MUSD
Access this data via the Eulerpool API

Compugen Stock analysis

What does Compugen do? Compugen Ltd is an Israeli biotechnology company focused on the development of therapeutics and diagnostic products. It was founded in 1993 and is headquartered in Tel Aviv. Compugen is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Compugen's Equity

Compugen's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Compugen's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Compugen's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Compugen's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Compugen’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Compugen stock

The Equity of Compugen is 102.73 M USD in 2026.

The Equity of Compugen changed from 54.91 M USD to 102.73 M USD, representing a 87.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Compugen since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Compugen historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Compugen

All Key Metrics — Compugen